We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Cancers Cured by Minimally Invasive Irreversible Electroporation Treatment

By Biotechdaily staff writers
Posted on 28 Feb 2007
A recent publication described the use of irreversible electroporation (IRE) as a minimally invasive surgical technique to selectively destroy cancer cells while leaving surrounding structural tissues and blood vessels undamaged.

Irreversible electroporation uses electrical pulses to poke holes in cell membranes that do not reseal, causing the cells to die. More...
IRE utilizes a range of electrical current that causes permanent damage to cell membranes without generating heat and thermal damage. Investigators at the Hebrew University of Jerusalem (Jerusalem, Israel) performed the IRE surgical technique on 14 healthy female pigs under general anesthesia, using the same procedures as if the patients were human.

Results published in the February 2007 issue of Technology in Cancer Research and Treatment revealed that selected cell membranes were destroyed, while untargeted adjacent tissue healed remarkably quickly. Although the tissue chosen for destruction in this study was healthy, the investigators had found in a prior cell culture study that IRE effectively killed human liver cancer tissue.

"I have been working in this area of minimally invasive surgery for 30 years now,” said senior author Dr. Boris Rubinsky, professor of bioengineering at the Hebrew University of Jerusalem. "This concept of reversible electroporation really caught on in modern biotechnology, especially over the last decade. It is used primarily to help get genes and drugs into cells. The field of irreversible electroporation was pretty much forgotten. I truly think that this will be viewed as one of the most important advances in the treatment of tumors in years. I am very excited about the potential of this technique. It may have tremendous applications in many areas of medicine and surgery.”


Related Links:
Hebrew University of Jerusalem

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.